Invivyd (IVVD) Cash from Financing Activities (2021 - 2025)
Invivyd's (IVVD) quarterly Cash from Financing Activities came in at $157.2 million in Q4 2025, up 204025.97% on a YoY basis from N/an in Q4 2024, and up 169.54% quarter-over-quarter from $58.3 million in Q3 2025.
Analysis
Invivyd (IVVD) Cash from Financing Activities (2021 - 2025) Analysis & Trends
Invivyd (IVVD) has reported Cash from Financing Activities for 5 consecutive years, with $157.2 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities rose 204025.97% year-over-year to $157.2 million; the trailing twelve-month figure through Dec 2025 stood at $215.6 million (up 448.24% YoY), and the FY2025 full-year result was $215.6 million, up 448.24% from the prior year.
- Cash from Financing Activities improved to $157.2 million in Q4 2025 per IVVD's latest filing, from $58.3 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $334.8 million in Q2 2021 and bottomed at -$749000.0 in Q4 2021.
- Historically, Cash from Financing Activities has averaged $48.4 million across 5 years, with a median of $141000.0 in 2022.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities sank 99.98% in 2022, then surged 204025.97% in 2025.
- Over 5 years, Cash from Financing Activities stood at -$749000.0 in 2021, then jumped by 118.83% to $141000.0 in 2022, then changed by 0.0% to $141000.0 in 2023, then slumped by 45.39% to $77000.0 in 2024, then soared by 204025.97% to $157.2 million in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $157.2 million, $58.3 million, and $131000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | -1.48 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 2.34 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | -426.70 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | -1.22 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 14.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 1.30 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 157.18 Mn |
| Sep 30, 2025 | 58.31 Mn |
| Jun 30, 2025 | 131,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Jun 30, 2024 | 92,000.00 |
| Mar 31, 2024 | 39.10 Mn |
| Dec 31, 2023 | 141,000.00 |
| Sep 30, 2023 | 92,000.00 |
| Jun 30, 2023 | 270,000.00 |
| Mar 31, 2023 | 542,000.00 |
| Dec 31, 2022 | 141,000.00 |
| Sep 30, 2022 | 246,000.00 |
| Jun 30, 2022 | 74,000.00 |
| Mar 31, 2022 | 45,000.00 |
| Dec 31, 2021 | -749,000.00 |
| Sep 30, 2021 | 328.60 Mn |
| Jun 30, 2021 | 334.83 Mn |